02/11
Headlines

NASDAQ:INFI

Gilead Sciences GILD NASDAQ:GILD

Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Mark DeFrance03 mins

Bristol-Myers Squibb Co (NYSE:BMY) and Urban Outfitters (URBN) retreated 6.1 percent and 3.6 percent respectively, after brokers lowered their ratings on these stocks. Weaker-than-expected first-quarter results and dismal second-quarter earnings guidance led Wal-Mart Stores (WMT) to drop 2.4 per cent. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -6.12% in last session and finished the day…

Read More

Losers At Healthcare: Synageva BioPharma (NASDAQ:GEVA), Auspex Pharmaceuticals (NASDAQ:ASPX), ImmunoGen (NASDAQ:IMGN), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Mark Doerr02 mins

Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year. Synageva BioPharma Corp (NASDAQ:GEVA)stock performance was 5.87% in…

Read More

Biotech Bearish Stocks: Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Corcept Therapeutics Incorporated (NASDAQ:CORT), Puma Biotechnology Inc (NYSE:PBYI), Conatus Pharmaceuticals (NASDAQ:CNAT)

Mark DeFrance02 mins

A Palo Alto startup will focus an $18 million VC investment on developing a drug to stop unexplained recurrent miscarriages. Nora Therapeutics is capitalizing on work started by cofounder Darryl Carter at Johns Hopkins University that led to development of Nora’s lead drug, NT-100. Nora is led by CEO Jeff Tong, who had been vice…

Read More

Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Mark Doerr02 mins

Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy),…

Read More